Bio-Rad Laboratories, Inc. BIO is well-poised to grow in the upcoming quarters, courtesy of its strong traction in the QX600 Droplet Digital PCR (ddPCR) platform. Demand for its quality control and ...
Bio-Rad Laboratories, Inc. BIO is well-poised to grow in the upcoming quarters, given the demand for its quality control and immunology products in Clinical Diagnostics. In addition, growth across ...
Q1 2025 Management View CEO Norman Schwartz noted that despite macroeconomic headwinds, the company is focusing on long-term opportunities in life science research and diagnostics markets. Schwartz ...
Bio-Rad remains undervalued, but persistent end-market headwinds and limited core growth drivers temper my conviction. BIO's valuation is heavily influenced by its substantial Sartorius stake, and the ...
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the ...
12d
Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026
Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year 2025 on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results